Tafasitamab for the treatment of patients with diffuse large B-cell lymphoma
作者：
Pirosa, Maria Cristina;Stathis, Anastasios;Zucca, Emanuele
通讯作者：
Maria Cristina Pirosa
作者机构：
Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Institute of Oncology Research, Bellinzona, Switzerland
Faculty of Biomedical Science, Universita’ della Svizzera italiana, Lugano, Switzerland
通讯机构：
Clinic of Medical Oncology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland
Institute of Oncology Research, Bellinzona, Switzerland
Faculty of Biomedical Science, Universita’ della Svizzera italiana, Lugano, Switzerland
语种：
英文
关键词：
DLBCL;relapsed-refractory disease;monoclonal antibodies;Anti CD-19 agent;Tafasitamab
期刊：
Human Vaccines & Immunotherapeutics
ISSN：
2164-5515
年：
2024
卷：
20
期：
1
页码：
2309701
基金类别：
The author(s) reported there is no funding associated with the work featured in this article.
摘要：
Diffuse large B-cell lymphoma is the most common subtype accounting for 30–40% of non-Hodgkin’s lymphoma (NHL) cases in the Western countries.1It is an heterogeneous disease presenting subty...
